Definitive Healthcare (NASDAQ:DH) Updates Q3 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its third quarter 2026 earnings guidance on Monday. The company provided EPS guidance of 0.040-0.050 for the period, compared to the consensus estimate of 0.040. The company issued revenue guidance of $54.0 million-$55.0 million, compared to the consensus revenue estimate of $55.5 million. Definitive Healthcare also updated its FY 2026 guidance to 0.180-0.200 EPS.

Definitive Healthcare Stock Down 7.8%

Shares of DH stock opened at $0.64 on Wednesday. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.81. Definitive Healthcare has a 12 month low of $0.62 and a 12 month high of $4.35. The stock has a market cap of $67.92 million, a P/E ratio of -0.40, a P/E/G ratio of 11.27 and a beta of 1.35. The company has a 50 day simple moving average of $0.77 and a two-hundred day simple moving average of $1.10.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings results on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a negative net margin of 77.00% and a positive return on equity of 3.18%. The business had revenue of $55.20 million for the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. On average, research analysts expect that Definitive Healthcare will post 0.04 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DH. Morgan Stanley lowered their target price on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th. Robert W. Baird set a $1.10 price objective on Definitive Healthcare in a research note on Friday, May 8th. Finally, Zacks Research raised shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $1.55.

Institutional Trading of Definitive Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in Definitive Healthcare in the 2nd quarter worth approximately $32,000. Schonfeld Strategic Advisors LLC purchased a new stake in Definitive Healthcare during the 4th quarter valued at approximately $35,000. HRT Financial LP bought a new stake in shares of Definitive Healthcare during the fourth quarter valued at approximately $47,000. ExodusPoint Capital Management LP purchased a new position in shares of Definitive Healthcare in the fourth quarter worth $47,000. Finally, Bayesian Capital Management LP bought a new position in shares of Definitive Healthcare during the second quarter worth $55,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.